or
Bookmark and Share
Process for the preparation of optically pure diastereoisomers of tetrahydrofolate compounds using 10-formyltetrahydrofolate synthetase from clostridium
   
Document Number
US Patent 5334535
Issued Date
August 2, 1994
Link
Map
Abstract
A process for the preparation of optically pure diastereoisomers of tetrahydrofolate compounds is described, comprising the conversion, for example, of only the 5,6S,7,8-tetrahydrofolic acid component of a racemic mixture of 5,6,7,8-tetrahydrofolic acid to 10-formyl-5,6S,7,8-tetrahydrofolic acid in the presence of a formyl tetrahydrofolate synthetase, followed by cyclizing, hydrolyzing and derivatizing. The process is also useful to make a desired substantially pure (6R or 6S) enantiomer of a derivative of (radiolabeled) tetrahydrofolic acid or a salt or ester thereof.
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
1
Comments:
no comments yet
Owner
Published
August 2, 1994
Application Number
07/947,641
Filed
September 18, 1992
US Classification
435/280   435/110 435/842 544/258
Int'l Classification
C07D   475/00   (20060101)   C12P   17/18   (20060101)   C12P   41/00   (20060101)   C07D   475/04   (20060101)   C12N   9/00   (20060101)  
Assistant Examiner
Attorney/Law Firm
Parent Case
This is a continuation of co-pending application Ser. No. 07/449,662, filed on Dec. 11, 1989, now abandoned.
USPTO Field of Search
435/280   435/110   435/842  
Related Patents
6011040 - Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine - Owned by Eprova AG (Schaffhausen,CH)

This invention relates to the use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine. Clinical areas of application include all anomalies of the homocysteine level, particularly the prevention and treatment of cardiovascular diseases and the prevention of neural tube deficiencies. The present invention also relates to pharmaceutical preparations comprising at least one compound selected from the group consisting of 5-formyl-(6S)-tetrahydrofolic acid, 5-methyl-(6S)-tetrahydrofolic acid, 5,10-methylene-(6R)-tetrahydrofolic acid, 5,10-methenyl-(6R)-tetrahydrofolic acid, 10-formyl-(6R)-tetrahydrofolic acid, 5-formimino-(6S)-tetra-hydrofolic acid or (6S)-tetrahydrofolic acid or pharmaceutically compatible salts thereof, together with pharmaceutically compatible active and adjuvant substances, for influencing the homocysteine level, particularly when a methylene tetrahydrofolate reductase deficiency exists, such as when thermolabile methylene tetrahydrofolate reductase exists for example.

5457202 - Resolution of 5-methyltetrahydrofolic acid - Owned by Knoll Aktiengesellschaft (Ludwigshafen,DE)

A process for preparing (6S)-5-methyltetrahydrofolic acid by resolution of racemic (6R,S)-5-methyltetrahydrofolic acid using a base, wherein the base is N-ethyl-2-aminomethylpyrrolidine or its optical isomers.

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us